The pro- and anti-tumor role of ILC2s

Sara Trabanelli; Mathieu F Chevalier; Laurent Derré; Camilla Jandus

doi:10.1016/j.smim.2019.04.004

The pro- and anti-tumor role of ILC2s

Semin Immunol. 2019 Feb:41:101276. doi: 10.1016/j.smim.2019.04.004. Epub 2019 May 23.

Authors

Sara Trabanelli¹, Mathieu F Chevalier², Laurent Derré³, Camilla Jandus⁴

Affiliations

¹ Departement of Oncology, UNIL-CHUV, University of Lausanne, 1066, Epalinges, Switzerland.
² Urology Research Unit, University Hospital of Lausanne (CHUV), 1011, Lausanne, Switzerland; INSERM U976, Laboratory of Human Immunology, Pathophysiology and Immunotherapy, Hôpital Saint-Louis, Paris, France; Université de Paris, Institut de Recherche Saint Louis, Hôpital Saint-Louis, Paris, France.
³ Urology Research Unit, University Hospital of Lausanne (CHUV), 1011, Lausanne, Switzerland.
⁴ Departement of Oncology, UNIL-CHUV, University of Lausanne, 1066, Epalinges, Switzerland. Electronic address: Camilla.Jandus@chuv.ch.

PMID: 31130471
DOI: 10.1016/j.smim.2019.04.004

Abstract

Group 2 innate lymphoid cells (ILC2s) are critical for the initiation of type 2 inflammatory diseases. However, ILC2s are also involved in the establishment of the immune microenvironment during tumor development, growth and metastasization. In this context, ILC2s have been shown to be either tumor-suppressive or tumor-promoting according to the tumor type, the cytokine secreted and the other immune cells that are, in turn, recruited and/or activated.

Keywords: Cancer; Group-2 innate lymphoid cells; ILC2; Tumor immunoregulation.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Cytokines / metabolism
Disease Susceptibility*
Humans
Immunity, Innate*
Lymphocyte Subsets / immunology
Lymphocyte Subsets / metabolism
Lymphocytes / immunology*
Lymphocytes / metabolism*
Neoplasms / etiology*
Neoplasms / metabolism*
Neoplasms / pathology
Tumor Microenvironment / immunology

Substances

Cytokines